-transparent.png){kind=logo}
Using highly purified recombinant human prorenin, we report the first evidence for the formation of a stable, partially active, conformational variant of the recombinant proenzyme. The enzymatically active prorenin exhibits the following characteristics: (1) the proenzyme N-terminal sequence and molecular weight are maintained; (2) the active proenzyme is capable of cleaving a novel fluorogenic peptide substrate based on the sequence of human angiotensinogen and exhibits about 30% of mature renin specific activity for the fluorogenic substrate; (3) the active proenzyme conformation binds to, and can be eluted from, a pepstatin affinity column; and (4) the activity of the active proenzyme can be inhibited by a novel peptidomimetic renin inhibitor.
R Edalji, and
T F Holzman, and
E J Gubbins
June 1992,
The Journal of biological chemistry,
R Edalji, and
T F Holzman, and
E J Gubbins
May 1988,
The Journal of clinical endocrinology and metabolism,
R Edalji, and
T F Holzman, and
E J Gubbins
April 1987,
Biotechnology and applied biochemistry,
R Edalji, and
T F Holzman, and
E J Gubbins
June 1988,
Hypertension (Dallas, Tex. : 1979),
R Edalji, and
T F Holzman, and
E J Gubbins
January 1988,
Peptides,
R Edalji, and
T F Holzman, and
E J Gubbins
August 2009,
Analytical chemistry,
R Edalji, and
T F Holzman, and
E J Gubbins
July 1988,
Journal of chromatography,
R Edalji, and
T F Holzman, and
E J Gubbins
March 1996,
Acta obstetricia et gynecologica Scandinavica,
R Edalji, and
T F Holzman, and
E J Gubbins
June 1995,
Journal of human hypertension,
R Edalji, and
T F Holzman, and
E J Gubbins
June 2024,
Hypertension (Dallas, Tex. : 1979),
